

Open

Correction: The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1–6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7–34 pathogenic variant

Julie W. Rutten, MD, PhD^{1,2}, Bastian J. Van Eijnsden, BSc¹, Marco Duering, MD³, Eric Jouvent, MD, PhD⁴, Christian Opherk, MD⁵, Leonardo Pantoni, MD, PhD⁶, Antonio Federico, MD, PhD⁷, Martin Dichgans, MD, PhD³, Hugh S. Markus, MD, PhD⁸, Hugues Chabriat, MD, PhD⁴ and Saskia A. J. Lesnik Oberstein, MD, PhD¹

Genetics in Medicine (2018) <https://doi.org/10.1038/s41436-018-0306-z>

Correction to: *Genetics in Medicine* ; <https://doi.org/10.1038/s41436-018-0088-3>; published online 22 July 2018

This Article was originally published under Nature Research's License to Publish, but has now been made available under a [CC BY 4.0] license. The PDF and HTML versions of the Article have been modified accordingly.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

¹CADASIL Research Group, Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; ²Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; ³Institute for Stroke and Dementia Research, University Hospital (LMU), Munich, Germany; ⁴Department of Neurology, AP-HP, Lariboisière Hospital, Paris, France; ⁵Department of Neurology, SLK-Kliniken Heilbronn, Heilbronn, Germany; ⁶“L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; ⁷Department of Medicine, Surgery and Neurosciences, Medical School, University of Siena, Siena, Italy; ⁸Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. Correspondence: Julie W. Rutten (j.w.rutten@lumc.nl)